These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 27843622)

  • 1. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.
    Kümler I; Knoop AS; Jessing CA; Ejlertsen B; Nielsen DL
    ESMO Open; 2016; 1(4):e000062. PubMed ID: 27843622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
    Reinert T; Barrios CH
    Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
    Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
    Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
    Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
    Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
    N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
    Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
    Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
    Bidard FC; Hardy-Bessard AC; Dalenc F; Bachelot T; Pierga JY; de la Motte Rouge T; Sabatier R; Dubot C; Frenel JS; Ferrero JM; Ladoire S; Levy C; Mouret-Reynier MA; Lortholary A; Grenier J; Chakiba C; Stefani L; Plaza JE; Clatot F; Teixeira L; D'Hondt V; Vegas H; Derbel O; Garnier-Tixidre C; Canon JL; Pistilli B; André F; Arnould L; Pradines A; Bièche I; Callens C; Lemonnier J; Berger F; Delaloge S;
    Lancet Oncol; 2022 Nov; 23(11):1367-1377. PubMed ID: 36183733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
    Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM
    J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer.
    Boér K
    Onco Targets Ther; 2016; 9():6119-6125. PubMed ID: 27785059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
    Zhang J; Huang Y; Wang C; He Y; Zheng S; Wu K
    Medicine (Baltimore); 2017 Aug; 96(33):e7846. PubMed ID: 28816986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.